FDA Brief

Warning letters Drugs

FDA warning letter to

Kellin Chemicals Co., Ltd. - Zhangjiagang

High riskIssued Nov 6, 2025Posted Sep 29Center for Drug Evaluation and Research (CDER)

Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.

What happened

FDA scheduled an inspection of Kellin Chemicals' drug manufacturing site from July 7 to July 11, 2025, and the company's U.S. agent told FDA the firm refused the preannounced inspection. FDA cites the refusal as making the company's drugs adulterated under the FD&C Act. The firm is registered as a supplier of active pharmaceutical ingredients (APIs) to finished-drug makers that sell to the U.S. market.

What FDA found

  1. The company refused to let FDA inspect its drug manufacturing facility after FDA gave notice of a planned inspection.

    Section 501(j) of the FD&C Act, 21 U.S.C. 351(j)
  2. Because the company refused inspection, FDA treats the drugs made there as adulterated.

    Section 501(j) of the FD&C Act, 21 U.S.C. 351(j)
  3. FDA may detain or refuse U.S. shipments that appear adulterated or misbranded.

    Section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3)

What FDA wants

FDA asks the company to respond in writing within 15 working days and says it may provide more information or request an inspection; FDA also recommends informing U.S. customers about the letter.

Who should pay attention

  • U.S. finished-drug manufacturers using Kellin APIs
  • brands and suppliers sourcing APIs from China
  • regulatory teams tracking supplier inspection status

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  2. Jagsonpal Pharmaceuticals Limited

    Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

    High risk
  3. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.

    FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.

    High risk
  4. Mei Lan Thailand Co., Ltd.

    Mei Lan Thailand, an API drug manufacturer, refused an FDA inspection and was placed on Import Alert 55-03.

    High risk